CRITICAL ROLE OF CYTOSOLIC PHOSPHOLIPASE A2a IN BRONCHIAL

MUCUS HYPER-SECRETION IN CFTR-DEFICIENT MICE

Fariel Dif<sup>1,2</sup>, Yong-Zheng Wu<sup>1,2</sup>, Pierre-Régis Burgel<sup>3</sup>, Mario Ollero<sup>4</sup>, Dominique Leduc<sup>1,2</sup>,

Jamil Aarbiou<sup>5</sup>, Florence Borot<sup>4</sup>, Ignacio Gacria-Verdugo<sup>1,2</sup>, Clémence Martin<sup>3</sup>, Michel

Chignard<sup>1,2</sup>, Dominique Israel-Biet<sup>6</sup>, Yoshihiro Kita<sup>7</sup>, Bob J. Scholte<sup>5</sup>, Lhousseine Touqui<sup>1,2</sup>

<sup>1</sup>Unité de Défense Innée et Inflammation, <sup>2</sup>Unité Inserm U. 874, Institut Pasteur, Paris;

<sup>3</sup>Université René Descartes, UPRES EA 2511, Hôpital Cochin AP-HP, Paris; <sup>4</sup>Inserm U845,

Université Paris Descartes, Paris; <sup>5</sup> Erasmus MC, Cell Biology department Rotterdam, The

Netherlands, <sup>6</sup>Service de Pneumologie, Hôpital Européen Georges Pompidou, Paris France;

<sup>7</sup>Department of Biochemistry and Molecular Biology, Faculty of Medicine, Tokyo.

\$ Contributed equally to the work

Corresponding author:

L. Touqui: touqui@pasteur.fr, Fax number: 33/1 45 68 87 03

This work was supported in part by a *Contrat de Recherche* with the French Associations

"Vaincre la Mucoviscidose" and "DARRI, Institut Pasteur. F. Dif was supported by "Vaincre

la Mucoviscidose". Jamil Aarbiou and Ruvalic Buijs-Offerman were supported by grants

STW 6565 and EU FP6IMPROVED PRECISION LSHB-CT-2004-005213.

**Key words**: arachidonic acid, cystic fibrosis, lipopolysaccharide, MUC5AC, mucus,

phospholipase A2

**RUNNING TITLE**: Phospholipase A2-induced mucus production in cystic fibrosis

#### Abstract

**Background:** Cystic fibrosis (CF) is due to mutations in the CF transmembrane conductance regulator gene *CFTR*. CF is characterized by mucus dehydration, chronic bacterial infection and inflammation, and increased levels of cytosolic phospholipase  $A2\alpha$  (cPLA2 $\alpha$ ) products in airways.

**Objective**: To examine the role of cPLA2 $\alpha$  in the modulation of mucus production and inflammation in CFTR-deficient mice and epithelial cells.

**Methods:** Mucus production was assessed using histological analyses, immuno-histochemistry and MUC5AC ELISA. cPLA2 $\alpha$  activation was measured using an enzymatic assay and lung inflammation determined by histological analyses and polymorphonuclear neutrophil counts in bronchoalveolar lavages.

**Results**: In lungs from *Cftr* -/- mice, LPS induced mucus overproduction and MUC5AC expression associated with an increased cPLA2α activity. Mucus overproduction was mimicked by instillation of the cPLA2α product arachidonic acid, and abolished by either a cPLA2α null mutation or pharmacological inhibition. An increased cPLA2α activity was observed in bronchial explants from CF patients. CFTR silencing induced cPLA2α activation and MUC5AC expression in bronchial human epithelial cells. This expression was enhanced by arachidonic acid and reduced by cPLA2α inhibition. However, inhibition of CFTR chloride transport function had no effect on MUC5AC expression.

**Conclusions:** Reduction of CFTR expression increases cPLA2 $\alpha$  activity. This leads to an enhanced mucus production in airway epithelia independent from CFTR chloride transport function. cPLA2 $\alpha$  represents a suitable new target for therapeutic intervention in CF.

#### INTRODUCTION

Cystic fibrosis (CF) is a common recessively inherited disorder in Caucasian population due to mutations in the CF transmembrane conductance regulator gene *CFTR*. The most common mutation results in the absence of a phenylalanine residue at amino-acid position 508 (F508del) [1]. Mutations of *CFTR* cause dysfunction of chloride and sodium channels leading to airway mucus abnormality, a critical pathophysiological feature of CF [2]. This leads to airway obstruction, chronic bacterial infection, in particular by *Pseudomonas aeruginosa*, and inflammation that results in a dramatic respiratory insufficiency, the major cause of mortality in CF patients [3-5].

Normally, the epithelium of conducting airways is covered with a thin layer of mucus that plays important roles in airway defense against inhaled pathogens by facilitating their clearance via mucociliary clearance to the upper airways [6-8]. Mucins are large glycoproteins secreted in the airway lumen by epithelial and submucosal gland cells. Mucins MUC5AC and MUC5B have been identified as important components of airway mucus in normal subjects [9]. In patients with CF, airway disease is characterized by progressive airway obstruction by mucous secretions [10]. Studies of mucins in CF airways excised at the time of transplantation have shown that: (i) MUC5AC mRNA expression is increased in CF epithelium compared to the epithelium of control subjects [11], (ii) immunostaining for MUC5AC protein is increased in CF epithelium compared with control subjects [12, 13], (iii) MUC5AC protein is present in the airway lumen of CF subjects, contributing to airway plugging [12, 13] and (iv) MUC5B is also increased in CF airway epithelium and lumen [12, 13]. Altogether these data suggest that overproduction and secretion of MUC5AC and MUC5B mucins may occur in CF airways and contribute to their progressive plugging. A recent paper by Garcia et al shows that CFTR activity is required for normal hydration and secretion of intestinal mucin in a mouse model of CF. It is inferred that a similar mechanism may play a role in CF airways [14]. This does not exclude mucus hypersecretion and goblet cell hyperplasia as contributing factors.

Many studies have examined the mechanisms involved in the induction of pulmonary mucus hypersecretion and mucin expression in various animal models of asthma [15, 16] and COPD [17]. Although CFTR mutations have been shown to induce mucus dehydration and accumulation, the impact of these mutations on mucin expression is still unclear. This expression can be a direct consequence of CFTR alteration or secondary to the exacerbated inflammation that CFTR alteration induces in the lung. Although increased production of various arachidonic acid (AA) metabolites, including leukotriene B4 (LTB4), has been reported in airways of CF patients [18]the levels of cysteinyl leukotrienes, known to induce

mucus production [16, 19], remained unknown. We have recently shown that a key enzyme involved in the release of AA, cytosolic phospholipase  $A2\alpha$  (cPLA2 $\alpha$ ), forms complexes with CFTR, and therefore it may play a critical role in the pathogenesis of CF [20]. cPLA2 $\alpha$  hydrolyses membrane phospholipids at the sn-2 position leading to a selective release of AA [21, 22]. The latter is further converted by cyclooxygenase (COX) and lipoxygenase (LOX) into prostaglandins (PG) and leukotrienes (LT), respectively [23, 24], among other mediators. The implication of cPLA2 $\alpha$  in the development of lung inflammation has been extensively examined in various animal models of lung inflammatory diseases [25-27] but its involvement in CF and in particular in airway mucus secretion has not been addressed. The present study aimed to investigate the role of cPLA2 $\alpha$  in LPS-induced lung mucus production in a mouse model of CF (*cftr* -\formule mice) and CFTR-deficient human bronchial epithelial cells.

## **Materials and Methods**

*Mice.* Cftr <sup>-/-</sup> (C57BL/6J Cftr<sup>m1UNC</sup>), established by gene targeting [28] were obtained from the "Centre de Distribution, de Typage et d'Archivage Animal" (Orleans, France). After weaning, a commercial osmotic laxative (Movicol®) was provided in the drinking water to increase the survival of Cftr <sup>-/-</sup> mice. C57BL/6J/cPLA2α-null mice were established as previously reported [27] and fed a standard laboratory diet and water. Experiments were performed on 8-12 week-old mice, using at least 6 mice in each group. Mice were cared for in accordance with Pasteur Institute guidelines in compliance with European animal welfare regulations.

#### LPS and ATK instillations

Mice were anesthetized with Xylazine 2% (8 mg/kg) (Rompum, Bayer-France) and Ketamine 1000 (40 mg/kg) (Imalgène1000 Merial, Lyon-France) and treated with the cPLA2α inhibitor, arachidonyl trifluoromethyl ketone (ATK) (Sigma, St. Louis, MO) as previously described [29]. Briefly, mice received intraperitoneal instillation of ATK (20 mg/Kg) in 20 % ethanol solution, or the same volume of this solution. One hour later, mice received intratracheal instillation of *P. aeruginosa* LPS (330 μg/kg in 20 μl PBS) (serotype 10; Sigma, St. Louis, MO). Mice received a second intraperitoneal instillation of ATK (20 mg/Kg) 24 h later. Bronchoalveolar lavages (BAL) were performed with PBS, 24 h or four days after LPS instillation. PBS was introduced slowly over 1 min to minimize trauma and hence red blood cell contamination. The extent of inflammation was assessed by measuring polymorphonuclear neutrophil (PMN) counts performed as previously described [30].

### Tissue fixation and histologic staining of tissue sections

Lungs were flushed to remove blood, immersed in 4% formaldehyde for 48 h at 4°C and processed for paraffin inclusion. Analyses of cells present in the epithelia lining the small and the large intrapulmonary bronchi were determined as previously described [31]. Longitudinal and transversal sections of the major intrapulmonary bronchi of 5-µm thickness were prepared and stained with Hematoxylin /eosin (H&E), periodic acid-Schiff (PAS) or Alcian blue (AB; pH 2.4). Sections (5 sections per mouse) were made to visualize large and small airways in all experimental groups. Mucus scores were established in a double blinded fashion by counting AB-positive cells, in 30 fields per mouse on 400x magnification, by two independent observers

under the supervision of a pathologist, as previously reported [31, 32]. The score analyses are shown (Supplementary data, Table 1) and their statistical analyses performed as indicated in the section "statistical analyses".

#### *Immunohistochemistry*

MUC5AC immunohistochemisty. Paraffin sections (5 μm) of mouse lungs were stained with a specific monoclonal antibody directed against Muc5ac (clone 45 M1, Neomarkers, Fermont, CA). After 2 h at room temperature sections were washed with PBS containing 2% BSA for 30 min and incubated with an IgG conjugated horseradish peroxidase anti-mouse (Dako Cytomation Envision System, Carpinteria, CA). Sections were then washed and stained with Amino Ethyl Carbazol (Sigma, St. Louis, MO).

cPLA2α *immunohistochemistry*. Five μm sections of human bronchial explants were incubated with a specific rabbit polyclonal antibody raised against phospho-cPLA2α (1:50 dilution; Cell signalling, Boston, MA) at room temperature for 1 h. After washing with PBS sections were incubated with a biotinylated horse anti-rabbit antibody (1:200 dilution; Vector laboratories, Burlingame, CA). The revelation was carried out with avidin-biotin-peroxidase complex method (Elite ABC kit, Vector laboratories, Burlingame, CA).

## Epithelial cell incubations

NCI-H292 cells were grown in RPMI-1640 medium as previously described [33], pre-incubated with cPLA2α inhibitors methyl arachidonyl fluorophosphonate (MAFP) or Pyrrolidine-1 for 1 h before stimulation with LPS, TGFα or phorbol myristate acetate (PMA). The concentrations of these compounds were adopted based on previous publications. In other studies, cells were transfected with CFTR siRNA (Sigma, St. Louis, MO) and corresponding siRNA control using TransIT-siQUEST® transfection reagent according to manufacturer instructions (Mirus, Madison, WI). The cells were then incubated for 1 h with MAFP followed by 24 h stimulation with PMA.

### Measurements of cPLA2\alpha activity and free AA

Lung tissues and NCI-H292 cells were lysed according to Filgueiras *et al.* [34] and centrifuged for 5 min at 1,000 x g to remove debris. Protein concentrations in pellets were measured by using a kit from Pierce (Thermo Scientific, Rockford, IL). Extracts with equivalent protein contents were incubated for 30 min with 1 ml vesicles containing 6 nmoles of 1-palmitoyl-

2[<sup>14</sup>C]arachidonoyl-sn-glycero-3-phosphorylcholine (>53 mCi/mmol) (Perkin-Elmer, Boston, MA) and 4 nmoles of diacylglycerol (Sigma, St. Louis, MO), in the presence of 5 mM CaCl2 and 1 mM 2-mercaptoethanol [35]. This assay detects selectively cPLA2α activity as iPLA2 activity dot not require calcium, and 2-mercaptoethanol inhibits sPLA2 but not cPLA2α activity [35]. Then, measurements and calculations of cPLA2α activity were measured [35]. The levels of free AA were measured in BALF by gas chromatography/mass spectrometry as previously reported [36].

#### **MUC5AC ELISA**

Aliquots from cell lysates or cell cultures were incubated with bicarbonate-carbonate buffer (50 μl) at 40°C in a 96-well plate (Nalge Nunc International, Rochester, NY) until dry. Then, MUC5AC levels were measured by ELISA using a mouse monoclonal antibody directed against MUC5AC (clone 45 M1, Neomarkers, Fermont, CA) as previously reported [37]. This antibody is specific for MUC5AC.

## Interleukin - 8 and prostaglandin E2 measurements

Interleukin - 8 (IL-8) and prostaglandin E2 (PGE2) levels in cell cultures were determined using commercial ELISA and EIA kits from R&D Systems (Minneapolis, MN) and Cayman Chemicals (Ann Harbor, MI).

### Western blotting analysis

Lung tissues and NCI-H292 cells were lysed in lysis buffer (Buffer RLT from Qiagen, France) and RIPA buffer, respectively. Equivalent amounts of proteins per sample were loaded onto 7,5% Tris/Glycine/SDS-polyacrylamide gels. Blots were then incubated for 1h at room temperature with 1:200 dilution of a goat antibody specific for human cPLA2α (Santa-Cruz, sc-454) or a 1:1000 dilution of a mouse monoclonal antibody specific for human CFTR (Abcam, ab2784).

## Bronchial explants of CF and non-CF patients

Bronchial explants were obtained at transplantation from 10 adults with CF with F508del mutation and 7 non-CF patients with lung cancer (Supplementary data, Table 2), as previously reported [12]. None of these patients required invasive mechanical ventilation before the lung

transplantation procedure. The study conformed to the Declaration of Helsinki and to the rules of the Committee on Human Research of Hôpital Cochin, Paris, France.

# Statistical analyses

We performed comparisons among all groups by ANOVA, and between two subject groups by the two-tailed Student t-test using SPSS software. Levene's test was used to test the homogeneity of variance. Data are expressed as means  $\pm$  SE and p values less than 0.05 was considered significant.

## **RESULTS**

# Cftr - mice exhibit increased pulmonary mucus production and MUC5AC expression

Histological analyses of lung sections showed a normal structure, no inflammatory cells and no mucus-positive cells in  $Cfir^{+/+}$  mice. However, in  $Cfir^{-/-}$  mice, increased numbers of mucus-positive cells (Fig 1A) were detected as compared to  $Cfir^{-+/+}$  mice (see also mucus scores in Fig 1C, p < 0.05). Intratracheal instillation of *P. aeruginosa* LPS (330 µg/Kg) induced an intense bronchopneumonia (characterized by an accumulation of inflammatory cells inside the bronchial lumen and parenchyma) to a similar extent in the two mouse strains (Fig 1A). This dose of LPS (330 µg/Kg) has been shown to induce an optimal lung inflammation [30]. No significant differences in PMN counts (Supplementary data, Fig 1A) and MIP-2 concentration (unpublished observation) were observed in BAL fluids from the two strains. However, LPS increased the numbers of mucus-positive cells (Fig. 1A) in  $Cfir^{-/-}$  compared to  $Cfir^{-/-}$  mice (see mucus scores in Fig. 1C, p < 0.01). Enhanced mucus production in  $Cfir^{-/-}$  mice was more evident with AB than with PAS staining. Immuno-histochemical analyses revealed a higher number of MUC5AC-positive cells in the lungs of  $Cfir^{-/-}$  compared to  $Cfir^{-/-}$  mice (Fig 1B).

# Cftr → mice display an increased pulmonary cPLA2\alpha activity and AA release

An increased cPLA2 $\alpha$  activity was observed in lung homogenates of  $Cftr^{-/-}$  compared to  $Cftr^{+/+}$  mice, both in basal conditions (p < 0.05) or upon LPS challenge (p < 0.01) (Fig 2A). This was accompanied by an increase in the levels of free AA in  $Cftr^{-/-}$  compared to  $Cftr^{+/+}$  mice (p < 0.05) (Fig 2B). Similar levels of cPLA2 $\alpha$  protein (Supplementary data, Fig. 2A) were observed in lungs of  $Cftr^{-/-}$  and  $Cftr^{-/-}$  mice, before and after LPS challenge. The specific cPLA2 $\alpha$  inhibitor ATK [29] reduced cPLA2 $\alpha$  activity in lung homogenates by more than 80 % (p < 0.01) (Supplementary data, Fig. 2B). Thus, the observed increase in PLA2 activity is likely due (in large part) to an enhanced stimulation of cPLA2 $\alpha$  activity.

# cPLA2α regulates bronchial mucus production in Cftr -/- mice.

Intraperitoneal injection of ATK before intratracheal LPS instillation reduced AB staining (Fig. 3A vs Fig. 1A) in both  $Cftr^{-/-}$  and normal littermate mice (see mucus scores in Fig 1C, p < 0.01). ATK also abrogated the number of MUC5AC positive cells (Fig. 3B). However, ATK had no effect on the inflammatory status as shown by histological analyses (Fig 3A) and

PMN counts in BAL (Supplementary data, Fig.1 B). In contrast to cPLA2 $\alpha^{+/+}$  mice, no detectable mucus-positive cells were observed in cPLA2 $\alpha^{-/-}$  mice, both under basal conditions and after LPS instillation (Fig 4A and Fig 4B, p < 0.01). Intratracheal instillation of LPS induced an intense bronchopneumonia (Fig 4A). This was accompanied by increased PMN counts in BAL (Supplementary data, Fig 3). These processes were observed at similar intensities in wild type and cPLA2 $\alpha^{-/-}$  mice. Intratracheal instillation of AA to C57/Bl6 wild-type mice increased the number of mucus-positive cells (Fig 4C and D, p < 0.01). However, AA had no effect on PMN infiltration in lung tissues as shown by H & E staining (Fig. 4C).

## CF patients exhibit an increased bronchial cPLA2\alpha activity

A marked immuno-staining of the phosphorylated (active) form of cPLA2 $\alpha$  was observed in all sections from CF compared to non-CF patients. Positive staining was observed in the nuclei and plasma membranes of airway epithelial cells. Infiltrating inflammatory cells (e.g., neutrophils) were also positively stained (Fig 5A and B). Higher levels of cPLA2 $\alpha$  activity were found in homogenates of bronchial explants from CF compared to non-CF patients (Fig 5C, p < 0.01). This activity was significantly reduced by treating homogenates from CF patients with ATK (8422  $\pm$  300 vs 2415  $\pm$  187 dpm/mg, means  $\pm$  SE, n = 6, in control and ATK-treated homogenates, respectively, p < 0.01).

# CFTR modulates MUC5AC expression in NCI-H292 cells via a cPLA2α-dependent mechanism

We examined the role of cPLA2 $\alpha$  and CFTR in MUC5AC expression in the human lung epithelial cell line NCI-H292, which expresses both CFTR and cPLA2 $\alpha$  (supplementary data, Fig 4A and B). LPS, TGF $\alpha$  and PMA induced an increase of MU5AC levels in cell lysates (Fig. 6A and B) (p < 0.01). PMA is known to induce MUC5AC expression in NCI-H292 cells *via* matrix metalloprotease-mediated release of TGF- $\alpha$  [38]. MUC5AC levels were reduced by cPLA2 $\alpha$  inhibitors methyl arachidonyl fluorophosphonate (MAFP) and Pyrrolydine-1 (Fig. 6B) (p < 0.01), and enhanced by AA (Fig. 6C) (p < 0.01). Neither cPLA2 $\alpha$  inhibitors nor AA interfered with IL-8 secretion (data not shown).

Silencing of CFTR expression by siRNA reduced the levels of CFTR protein by  $72 \pm 7.5$  % (p < 0.01) and  $62 \pm 5.5$  % (p < 0.05) as compared to negative siRNA-treated and to untreated cells, respectively (Supplementary data Fig. 4 B and C). This led to an increased cPLA2 activity (Fig. 7A) (p < 0.01) and PGE2 release (Supplementary data, Fig 5A). This was

accompanied by increased MUC5AC levels in cell extracts (Fig. 7B) (p < 0.01) and cultures (Supplementary data, Fig 5B), both of which were reduced by MAFP. In contrast, pre-treating cells with the specific CFTR functional inhibitor CFTR<sub>inh</sub>-172 [39] failed to increase MUC5AC expression and even decreased it (Fig. 7C). As a positive control, we showed that CFTR<sub>inh</sub>-172 induced an increased IL-8 secretion under LPS (p < 0.05) and PMA (p < 0.01) stimulation (Fig 7D), which is considered as evidence of effective inhibition of CFTR function by CFTR<sub>inh</sub>-172. At this concentration CFTR<sub>inh</sub>-172 has been shown to inhibit specifically the CFTR Cl - function without interfering with the activity of other Cl- channels [39]. We conclude that the level of CFTR protein expression, but not CFTR transport activity, regulates cPLA2 $\alpha$  activity, and subsequently MUC5AC expression.

#### **DISCUSSION**

The present study shows that  $Cftr^{-/-}$  mice exhibit enhanced bronchial mucus production which is exacerbated by P aeruginosa LPS. This occurs through a process involving, at least in part, an up-regulation of  $cPLA2\alpha$  activity. In support of this, we showed that mucus production was abolished by a  $cPLA2\alpha$  null mutation or by a specific  $cPLA2\alpha$  inhibitor. Airway explants from CF patients also showed enhanced  $cPLA2\alpha$  activity mainly located in epithelial cells that have been shown to exhibit increased MUC5AC expression [12]. In a cell model, we showed that  $cPLA2\alpha$  activity and MUC5AC expression increase after reduction of CFTR expression. This MUC5AC expression was abrogated by  $cPLA2\alpha$  inhibition. However,  $cPLA2\alpha$  appears to play a minor role in LPS-induced inflammation in our experimental models. Indeed, neither  $cPLA2\alpha$  knock-out nor its pharmacological inhibition had any effect on PMN influx in the airways, or on IL-8 expression in epithelial cells. Although, our studies clearly indicate that  $cPLA2\alpha$  plays a key role in mucus production the implication of other PLA2 in this process cannot be excluded. Indeed, it has been shown that secreted phospholipases A2 stimulate mucus secretion in ferret trachea [40].

Our studies demonstrated an impact of CFTR dysfunction on mucus production in airway epithelial cells, both *in vitro* and *in vivo*, using three different methods (Immunohistochemistry, histological staining and ELISA). Our findings showing that *Cftr* -/- mice exhibit exacerbated bronchial mucus production is in agreement with a previous report [41] although this was contested in another one [42]. Differences in animal husbandry, experimental protocols or genetic background may explain this apparent discrepancy.

The enhanced cPLA2 $\alpha$  activity in *Cftr*  $^{-/-}$  mouse lung and human CF bronchial explants observed in the present work is in agreement with previous studies in human cell lines bearing the F508del mutation [43, 44]. In these cells, an abnormal cPLA2 $\alpha$  activity has been suggested to be a direct consequence of CFTR alteration. One plausible scenario is that CFTR acts as an inhibitor of cPLA2 $\alpha$  activity through a domain with high homology to annexin-1 [45], a cPLA2 $\alpha$  inhibitory protein [46, 47]. Consequently, the conditions that reduce CFTR levels would be expected to enhance cPLA2 $\alpha$  activity. It is established that F508del mutation leads to endoplasmic reticulum retention and rapid degradation of CFTR [48, 49]. The present studies show that CFTR silencing increases cPLA2 $\alpha$  activity in epithelial cells. In a recent

work [20], we presented evidence that cPLA2 $\alpha$  and CFTR form a complex, apparently through interaction with S100A10/annexin-1 and that the integrity of this complex may affect cPLA2 $\alpha$  activity. This is in agreement with previous reports demonstrating the ability of CFTR to form a complex with annexins II [50] and V [51]. Decreased annexin-1 levels have been reported in a mouse model of asthma [52] with a parallel stimulation of cPLA2 $\alpha$  activity. The expression of annexin-1 is strongly diminished in nasal cells from CF patients, as well as in lung of  $Cftr^{-1/2}$  mice [53]. Based on these reports and our findings that cPLA2 $\alpha$  activity is increased in lungs of  $Cftr^{-1/2}$  mice and CF patients, we hypothesize that alteration of levels of one of the components forming this putative complex might impact cPLA2 $\alpha$  activity. Whether this activity is increased in CF epithelial cells as a consequence of alteration of the levels of either CFTR or annexin-1, or both, remains to be elucidated.

We also showed that the CFTR functional inhibitor (CFTR<sub>inh</sub>-172) failed to induce MUC5AC expression in NCI-H292 cells suggesting that CFTR transport function may not play a major role in MUC5AC expression in this cell model. We suggest that in addition to the effects of CFTR chloride transport function on mucus properties [14], reduction of CFTR levels may modulate MUC5AC expression via a cPLA2 $\alpha$ -dependent mechanism. The fact that cPLA2 $\alpha$  inhibition abrogates PMA- and TGF $\alpha$ -induced MUC5AC expression suggests that EGFR-mediated mucus production occurs, at least in part through cPLA2 $\alpha$  activation. Indeed, PMA is known to induce MUC5AC expression in NCI-H292 cells *via* matrix metalloprotease-mediated release of TGF $\alpha$  and EGFR activation [38].

The stimulatory effect of CFTR transcriptional silencing on cPLA2 $\alpha$  activity and MUC5AC expression in epithelial cells suggests that MUC5AC expression in  $Cftr^{-/-}$  mice may occur in epithelial cells through an autocrine modulation of cPLA2 $\alpha$ . Alternatively, MUC5AC induction can occur in goblet cells by a paracrine stimulation by AA released from other epithelial cells. We hypothesize that cPLA2 $\alpha$  may play a role in mucus overproduction during the episodes of P. aeruginosa infection in CF patients. Indeed, we showed that: i) cPLA2 $\alpha$  mediates P. aeruginosa LPS-induced mucus overproduction in  $Cftr^{-/-}$  mouse lungs, ii) this enzyme plays a role in MUC5AC expression in CFTR-deficient human bronchial epithelial cells and iii) cPLA2 $\alpha$  activity increases in bronchial explants from CF patients. It should be stressed that study of non-infected lower airway tissues from living CF subjects is still a major challenge, since most patients will have chronic airway infection/colonization during the

course of the disease. Thus, although bronchial explants do not reflect basal state of these airways, it accurately reflects the *in vivo* state of airways in chronically infected/inflamed CF airways. Therefore, although our findings suggest a role for cPLA2 $\alpha$  in increased mucus production in CF patients, this increase can also be a secondary response to inflammation.

We conclude that reduction of CFTR expression in CF lungs leads to an enhanced activation of cPLA2 $\alpha$ , which in turn induces mucus overproduction. Induction of mucus production by cPLA2 $\alpha$  may contribute to the mucus related pathology seen in CF. A pharmacological approach based on the use of a cPLA2 $\alpha$  inhibitor attenuated mucus overproduction in both human epithelial cells and in *Cftr* -/- mice. We propose a potential therapeutic role for cPLA2 $\alpha$  inhibitors in reducing mucus accumulation in CF.

# Acknowledgments

We warmly thank V. Balloy for her helpful assistance for animal instillations. We are grateful to Dr. M. Huerre for expert advice and criticisms and P. Ave and S. Bergère for help on histological analyses. Martina Wilke and Ruvalic Buijs-Offerman are acknowledged for assistance in preparing the lung tissues and BALF samples.

#### **LEGENDS OF FIGURES**

# Figure 1. Enhanced mucus production in the respiratory tract of Cftr -- mice

A) Histological analyses. Cftr +/+ and Cftr -/- mice received intra-tracheal instillation of saline alone or containing LPS (330 µg/Kg) and analyses were performed 4 days later. Panels a, d, g, and i show H&E staining of paraffin sections of lung tissues from mice treated with saline (a and g) or LPS (d and j). Histopathologic examination of lung sections from mice treated with saline showed a normal structure and no inflammatory cells (a and g), in contrast to lungs from LPS-treated mice, which revealed bronchopneumonia (d and j). Bronchopneumonia characterized by accumulation of inflammatory cells inside the bronchial lumen and parenchyma. Panels b, e, h and k show Alcian-Blue (AB) staining of paraffin sections of lungs. No mucus-positive cells were detected in lung sections from saline-treated Cftr -/-+/+ mice (b). A moderate staining was detected in saline-treated Cftr +/+ -/- mice (h). In LPS-treated mice, mucus-positive cells were detected in Cftr -/- mice (k) at higher number than in Cftr -/-/- mice (e). Panels c, f, i and l show periodic acid-Schiff (PAS) staining. Mucus positive cells were detected with this staining both in Cftr +/+ (c, f) and Cftr -/- (i, l) mice. No differences were observed between the two mouse strains either after saline (c, i) or LPS (f, l) treatment. Mucuspositive cells are indicated by arrows. AB-positive cells are in blue and PAS-positive cells are in majenta (see Alcian blue and PAS panels, respectively). Green arrow shows bronchi and red arrow shows alveoli (see H & E panel). Bar =  $50 \mu m$ .





Figure 1

**B. Immunohistochemical analyses.** Immunohistochemical detection of MUC5AC was performed with an anti-MUC5AC antibody on lung sections from  $Cftr^{+/+}$  and  $Cftr^{-/-}$  mice. Mice were treated with saline (a and d) or LPS (b, c, e and f) and analyses performed 4 days later. No staining was observed in saline (a) or LPS-treated (b, c)  $Cftr^{+/+}$  mice. Saline-treated  $Cftr^{-/-}$  mice (d) showed little MUC5AC staining which increased after LPS instillation (e, f). MUC5AC-positive staining was associated with goblet cells (e and f). Bar = 50  $\mu$ m.







Figure 1

C) Mucus scores were determined based on AB-staining of lung sections shown on Figs. 1 and 4. \*\* p < 0.01 *Cftr*  $^{-/-}$  compared to *Cftr*  $^{+/+}$  mice; # p < 0.01 LPS-treated compared to saline-treated mice; \$ p < 0.01 ATK-treated compared to untreated mice.

Figure 2: Enhanced cPLA2 $\alpha$  activity and AA release in the respiratory tract of  $Cftr^{-/-}$  mice

A) cPLA2 $\alpha$  activity was measured in lung homogenates from  $Cftr^{+/+}$  and  $Cftr^{-/-}$  mice 24 h after LPS instillation, and expressed as dpm/mg of proteins in homogenates. B) Levels of free

AA were measured in BALF. \* < 0.05; \*\* p < 0.01 *Cftr*  $^{-/-}$  compared to *Cftr*  $^{+/+}$  mice. \$ p < 0.01 LPS- vs saline-treated mice.






Figure 2

Figure 3. Inhibition of mucus production by a cPLA2α inhibitor

**A) Histological analyses compared to Fig. 1.** *Cftr* +/+ and *Cftr* -/- mice were pretreated intraperitonealy with ATK (20 mg/Kg) or vehicle. Mice received intratracheal LPS instillation as detailled in the Methods. Panels a, d, g, and j show H&E staining of paraffin sections of lung obtained from saline-treated (a and g) or LPS-treated mice (d and j) mice. The histopathologic examination of saline-treated mice sections showed a normal structure and no inflammatory cells (a et g). Lung sections from LPS-treated mice (d and j) displayed with an accumulation of neutrophils. Panels b, e, h and k show AB staining and panels c, f, i and l show PAS staining of lung sections. No AB- or PAS-positive cells were detected in lung sections from either *Cftr* +/+

or  $Cftr^{-/-}$  mice treated with ATK. Bar = 50  $\mu$ m. The solvent of ATK, ethanol, had no effect (not shown).




Figure 3

B) Immunohistological analyses of LPS-induced MUC5AC expression in ATK-treated  $Cftr^{-/-}$  mice.  $Cftr^{-/-}$  mice received either ATK or its solvent ethanol alone before LPS instillation. ATK treatment reduced the number of MUC5AC-positive cells (c, d) compared to ethanol-treated mice (a, b) in which strong expression of MUC5AC is observed in goblet cells. Omission of the primary antibody or incubation with an irrelevant antibody showed no signal (not shown). Bar = 50  $\mu$ m.





Figure 3

Figure 4. Effect of cPLA2 knock down and AA instillation on bronchial mucus production

A. Histological analyses of cPLA2α <sup>-/-</sup> and cPLA2α <sup>+/+</sup> mice. Mice were treated intratracheally with either saline or LPS and analyses were performed 4 days later. Panels a, d, g, and j correspond to H&E staining of lung paraffin sections from mice treated with either saline or LPS. Saline-treated mice showed normal structure and no inflammatory cells (a and g). Lung sections from LPS-treated mice (d and j) showed bronchopneumonia with accumulation of neutrophils. Panels b, e, h and k correspond to AB-staining and panels c, f, i, and l show PAS-staining of lung sections. No AB-positive cells were detected in the lungs from saline-or LPS-treated cPLA2α <sup>-/-</sup> mice (h, k). Mucus-positive cells were detected in LPS-


treated (e), but not in saline-treated (b) cPLA2 $\alpha^{+/+}$  mice (d). No differences were observed by PAS-staining between the two mice stains after either saline (c, i) or LPS (f, l) treatment. Bar = 50  $\mu$ m.



**B. Mucus score of cPLA2\alpha** <sup>-/-</sup> **and cPLA2\alpha** <sup>+/+</sup> **mice.** Scores were determined based on AB-staining of lung sections shown in Fig 4A. \* p < 0.05, \*\* p < 0.01 cPLA2 $\alpha$  <sup>+/+</sup> compared to cPLA2 $\alpha$  <sup>-/-</sup> mice; # p < 0.01 LPS-treated compared to saline-treated cPLA2 $\alpha$  <sup>+/+</sup> mice.

C. Histological analyses of AA-treated mice. Wild-type mice were instilled intratracheally with either AA or its solvent alone (0.25 % BSA) and sacrificed 4 days later. Panels a, b and c correspond to solvent-treated mice; panels d, e and f correspond to AA-treated mice. Panels a and d show H&E staining of lung paraffin sections. Solvent-treated mice show a normal

structure and no inflammatory cells. Panel e shows mucus-positive cells (AB-staining) in lung tissue from AA-treated mice. No positive cells were detected in solvent-treated mice (b). PAS-staining shows almost a similar number of positive cells in solvent- and AA-treated mice (c, f). Mucus cells are identified by arrows. Bar =  $50 \mu m$ .







Figure 4

**D. Mucus scores of AA-treated mice.** Scores were determined based on AB-staining from lung sections shown in Fig. 4A and are expressed as arbitrary units. \*\* p < 0.01 AA-treated vs control mice.

Figure 5. Enhanced cPLA2 $\alpha$  activation in bronchial explants from CF patients. A. cPLA2 $\alpha$  phosphorylation was analyzed by immuno-histochemistry in sections of bronchial explants from 7 non-CF and 10 CF patients. A: Representative photomicrographs of staining

(arrow) and B: Score analysis of positive cells, performed on all patients. Strong immunostaining was observed in the nuclei and plasma membranes of airway epithelial cells from CF patients. C) cPLA2 $\alpha$  activity was measured in homogenates of bronchial explants from CF and non-CF patients. Omission of the primary antibody or incubation with an irrelevant antibody showed no signal (not shown).\*\* p < 0.05 CF vs non CF patients.






Figure 5

Figure 6 : Role of cPLA2 $\alpha$  in MUC5AC expression in NCI-H292 cells. A and B) Cells were incubated with MAFP (10  $\mu$ M), Pyrrolidine-1 (5  $\mu$ M) or their vehicle (DMSO), then stimulated for 24 h with LPS (10  $\mu$ g/ml) or TGF $\alpha$  (20 nM) (A), or PMA (30 nM) (B). C) Cells were incubated for 24 h with the indicated concentrations of AA. MUC5AC levels were measured in cell lysates. \$ p < 0.05, \$\$ p < 0.01 stimulated  $\nu$ s unstimulated cells. \* p < 0.05

and \*\* p < 0.01 inhibitor-treated vs untreated cells.

cells




Figure 7 : Effect of CFTR on cPLA2α activity and MUC5AC expression in NCI-H292

Figure 6

A and B) Cells were subjected to CFTR siRNA and pre-incubated with MAFP before stimulation with PMA (30 nM), then cPLA2 $\alpha$  activity (A) and MUC5AC concentrations (B) were measured 2h and 24 h later, respectively. C and D) After 1 h incubation with Inh-172 (10  $\mu$ M), cells were stimulated for 24 h with PMA (30 nM). MUC5AC (C) and IL-8 (D) levels were measured in cell lysates and supernatants, respectively.




Figure 7

### **REFERENCES**

- 1. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O'Riordan CR, Smith AE. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. *Cell* 1990: 63(4): 827-834.
- 2. Doring G, Gulbins E. Cystic fibrosis and innate immunity: how chloride channel mutations provoke lung disease. *Cell Microbiol* 2009: 11(2): 208-216.
- 3. Balough K, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. *Pediatr Pulmonol* 1995: 20(2): 63-70.
- 4. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. *Am J Respir Crit Care Med* 1995: 151(4): 1075-1082.
- 5. Wilson JM, Collins FS. Cystic fibrosis. More from the modellers. *Nature* 1992: 359(6392): 195-196.
- 6. Rogers DF. Airway goblet cells: responsive and adaptable front-line defenders. *Eur Respir J* 1994: 7(9): 1690-1706.
- 7. Rose MC. Mucins: structure, function, and role in pulmonary diseases. *Am J Physiol* 1992: 263(4 Pt 1): L413-429.
- 8. Voynow JA. What does mucin have to do with lung disease? *Paediatr Respir Rev* 2002: 3(2): 98-103.
- 9. Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. *Physiol Rev* 2006: 86(1): 245-278.
- 10. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. *N Engl J Med* 2005: 352(19): 1992-2001.
- 11. Dohrman A, Miyata S, Gallup M, Li JD, Chapelin C, Coste A, Escudier E, Nadel J, Basbaum C. Mucin gene (MUC 2 and MUC 5AC) upregulation by Gram-positive and Gramnegative bacteria. *Biochim Biophys Acta* 1998: 1406(3): 251-259.
- 12. Burgel PR, Montani D, Danel C, Dusser DJ, Nadel JA. A morphometric study of mucins and small airway plugging in cystic fibrosis. *Thorax* 2007: 62(2): 153-161.

- 13. Groneberg DA, Eynott PR, Oates T, Lim S, Wu R, Carlstedt I, Nicholson AG, Chung KF. Expression of MUC5AC and MUC5B mucins in normal and cystic fibrosis lung. *Respir Med* 2002: 96(2): 81-86.
- 14. Garcia MA, Yang N, Quinton PM. Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion. *J Clin Invest* 2009: 119(9): 2613-2622.
- 15. Morcillo EJ, Cortijo J. Mucus and MUC in asthma. *Curr Opin Pulm Med* 2006: 12(1): 1-6.
- 16. Singer M, Lefort J, Vargaftig BB. Granulocyte depletion and dexamethasone differentially modulate airways hyperreactivity, inflammation, mucus accumulation, and secretion induced by rmIL-13 or antigen. *Am J Respir Cell Mol Biol* 2002: 26(1): 74-84.
- 17. Rogers DF. The role of airway secretions in COPD: pathophysiology, epidemiology and pharmacotherapeutic options. *Copd* 2005: 2(3): 341-353.
- 18. Konstan MW, Walenga RW, Hilliard KA, Hilliard JB. Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. *Am Rev Respir Dis* 1993: 148(4 Pt 1): 896-901.
- 19. Kim YD, Kwon EJ, Park DW, Song SY, Yoon SK, Baek SH. Interleukin-1beta induces MUC2 and MUC5AC synthesis through cyclooxygenase-2 in NCI-H292 cells. *Mol Pharmacol* 2002: 62(5): 1112-1118.
- 20. Borot F VD, Faure G, Fritsch J,, Colas J, Moriceau S et al. Eicosanoid release is increased by membrane destabilization and CFTR inhibition in Calu-3 cells. *PLOS One* 2009;22;4(10):e7116.
- 21. Ghosh M, Tucker DE, Burchett SA, Leslie CC. Properties of the Group IV phospholipase A2 family. *Prog Lipid Res* 2006: 45(6): 487-510.
- 22. Six DA, Dennis EA. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. *Biochim Biophys Acta* 2000: 1488(1-2): 1-19.
- 23. Peters-Golden M, Canetti C, Mancuso P, Coffey MJ. Leukotrienes: underappreciated mediators of innate immune responses. *J Immunol* 2005: 174(2): 589-594.
- 24. Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. *J Clin Invest* 2001: 108(1): 15-23.
- 25. Bonventre JV, Huang Z, Taheri MR, O'Leary E, Li E, Moskowitz MA, Sapirstein A. Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. *Nature* 1997: 390(6660): 622-625.

- 26. Nagase T, Uozumi N, Ishii S, Kita Y, Yamamoto H, Ohga E, Ouchi Y, Shimizu T. A pivotal role of cytosolic phospholipase A(2) in bleomycin-induced pulmonary fibrosis. *Nat Med* 2002: 8(5): 480-484.
- 27. Uozumi N, Kume K, Nagase T, Nakatani N, Ishii S, Tashiro F, Komagata Y, Maki K, Ikuta K, Ouchi Y, Miyazaki J, Shimizu T. Role of cytosolic phospholipase A2 in allergic response and parturition. *Nature* 1997: 390(6660): 618-622.
- 28. Snouwaert JN, Brigman KK, Latour AM, Malouf NN, Boucher RC, Smithies O, Koller BH. An animal model for cystic fibrosis made by gene targeting. *Science* 1992: 257(5073): 1083-1088.
- 29. Nagase T, Uozumi N, Aoki-Nagase T, Terawaki K, Ishii S, Tomita T, Yamamoto H, Hashizume K, Ouchi Y, Shimizu T. A potent inhibitor of cytosolic phospholipase A2, arachidonyl trifluoromethyl ketone, attenuates LPS-induced lung injury in mice. *Am J Physiol Lung Cell Mol Physiol* 2003: 284(5): L720-726.
- 30. Chignard M, Balloy V. Neutrophil recruitment and increased permeability during acute lung injury induced by lipopolysaccharide. *Am J Physiol Lung Cell Mol Physiol* 2000: 279(6): L1083-1090.
- 31. Haile S, Lefort J, Joseph D, Gounon P, Huerre M, Vargaftig BB. Mucous-cell metaplasia and inflammatory-cell recruitment are dissociated in allergic mice after antibody-and drug-dependent cell depletion in a murine model of asthma. *Am J Respir Cell Mol Biol* 1999: 20(5): 891-902.
- 32. Yanagihara K, Seki M, Cheng PW. Lipopolysaccharide Induces Mucus Cell Metaplasia in Mouse Lung. *Am J Respir Cell Mol Biol* 2001: 24(1): 66-73.
- 33. Burgel PR, Lazarus SC, Tam DC, Ueki IF, Atabai K, Birch M, Nadel JA. Human eosinophils induce mucin production in airway epithelial cells via epidermal growth factor receptor activation. *J Immunol* 2001: 167(10): 5948-5954.
- 34. Filgueiras OM, Possmayer F. Characterization of phospholipase A2 from rabbit lung microsomes. *Lipids* 1987: 22(10): 731-735.
- 35. Hidi R, Vargaftig BB, Touqui L. Increased synthesis and secretion of a 14-kDa phospholipase A2 by guinea pig alveolar macrophages. Dissociation from arachidonic acid liberation and modulation by dexamethasone. *J Immunol* 1993: 151(10): 5613-5623.
- 36. Ollero M, Laposata M, Zaman MM, Blanco PG, Andersson C, Zeind J, Urman Y, Kent G, Alvarez JG, Freedman SD. Evidence of increased flux to n-6 docosapentaenoic acid in phospholipids of pancreas from cftr-/- knockout mice. *Metabolism* 2006: 55(9): 1192-1200.

- 37. Kohri K, Ueki IF, Nadel JA. Neutrophil elastase induces mucin production by ligand-dependent epidermal growth factor receptor activation. *Am J Physiol Lung Cell Mol Physiol* 2002: 283(3): L531-540.
- 38. Burgel PR, Nadel JA. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production in airway epithelium. *Thorax* 2004: 59(11): 992-996.
- 39. Perez A, Issler AC, Cotton CU, Kelley TJ, Verkman AS, Davis PB. CFTR inhibition mimics the cystic fibrosis inflammatory profile. *Am J Physiol Lung Cell Mol Physiol* 2007: 292(2): L383-395.
- 40. Okamoto K, Kim JS, Rubin BK. Secretory phospholipases A2 stimulate mucus secretion, induce airway inflammation, and produce secretory hyperresponsiveness to neutrophil elastase in ferret trachea. *Am J Physiol Lung Cell Mol Physiol* 2007: 292(1): L62-67.
- 41. Davidson DJ, Dorin JR, McLachlan G, Ranaldi V, Lamb D, Doherty C, Govan J, Porteous DJ. Lung disease in the cystic fibrosis mouse exposed to bacterial pathogens. *Nat Genet* 1995: 9(4): 351-357.
- 42. Cressman VL, Hicks EM, Funkhouser WK, Backlund DC, Koller BH. The relationship of chronic mucin secretion to airway disease in normal and CFTR-deficient mice. *Am J Respir Cell Mol Biol* 1998: 19(6): 853-866.
- 43. Berguerand M, Klapisz E, Thomas G, Humbert L, Jouniaux AM, Olivier JL, Bereziat G, Masliah J. Differential stimulation of cytosolic phospholipase A2 by bradykinin in human cystic fibrosis cell lines. *Am J Respir Cell Mol Biol* 1997: 17(4): 481-490.
- 44. Miele L, Cordella-Miele E, Xing M, Frizzell R, Mukherjee AB. Cystic fibrosis gene mutation (deltaF508) is associated with an intrinsic abnormality in Ca2+-induced arachidonic acid release by epithelial cells. *DNA Cell Biol* 1997: 16(6): 749-759.
- 45. Chap H. Une homologie frappante entre CFTR et les annexines. *Médecine/Science* 1991: 7: 8-9.
- 46. Flower RJ, Rothwell NJ. Lipocortin-1: cellular mechanisms and clinical relevance. *Trends Pharmacol Sci* 1994: 15(3): 71-76.
- 47. Kim S, Ko J, Kim JH, Choi EC, Na DS. Differential effects of annexins I, II, III, and V on cytosolic phospholipase A2 activity: specific interaction model. *FEBS Lett* 2001: 489(2-3): 243-248.

- 48. Engelhardt JF, Yankaskas JR, Ernst SA, Yang Y, Marino CR, Boucher RC, Cohn JA, Wilson JM. Submucosal glands are the predominant site of CFTR expression in the human bronchus. *Nat Genet* 1992: 2(3): 240-248.
- 49. Lukacs GL, Mohamed A, Kartner N, Chang XB, Riordan JR, Grinstein S. Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. *Embo J* 1994: 13(24): 6076-6086.
- 50. Borthwick LA, McGaw J, Conner G, Taylor CJ, Gerke V, Mehta A, Robson L, Muimo R. The formation of the cAMP/protein kinase A-dependent annexin 2-S100A10 complex with cystic fibrosis conductance regulator protein (CFTR) regulates CFTR channel function. *Mol Biol Cell* 2007: 18(9): 3388-3397.
- 51. Trouve P, Le Drevo MA, Kerbiriou M, Friocourt G, Fichou Y, Gillet D, Ferec C. Annexin V is directly involved in cystic fibrosis transmembrane conductance regulator's chloride channel function. *Biochim Biophys Acta* 2007: 1772(10): 1121-1133.
- 52. Chung YW, Oh HY, Kim JY, Kim JH, Kim IY. Allergen-induced proteolytic cleavage of annexin-1 and activation of cytosolic phospholipase A2 in the lungs of a mouse model of asthma. *Proteomics* 2004: 4(11): 3328-3334.
- 53. Bensalem N, Ventura AP, Vallee B, Lipecka J, Tondelier D, Davezac N, Dos Santos A, Perretti M, Fajac A, Sermet-Gaudelus I, Renouil M, Lesure JF, Halgand F, Laprevote O, Edelman A. Down-regulation of the anti-inflammatory protein annexin A1 in cystic fibrosis knock-out mice and patients. *Mol Cell Proteomics* 2005: 4(10): 1591-1601.